+86-28-82633987sales@biopurify.com
Batch Search
Alternate Text
Home > Product Category > Botanical Source > Myristicae Semen

Dehydrodiisoeugenol

CAS No.:2680-81-1

Dehydrodiisoeugenol
Catalogue No.: BP0463
Formula: C20H22O4
Mol Weight: 326.392
Botanical Source: Myristicae Semen
Contacts
+86-28-82633860  +86-18080483897
 
Email: sales@biopurify.com biopurify@gmail.com

Dehydrodiisoeugenol

CAS No.:2680-81-1

Dehydrodiisoeugenol
Catalogue No.: BP0463
Formula: C20H22O4
Mol Weight: 326.392
Botanical Source: Myristicae Semen
Contacts
+86-28-82633860  +86-18080483897
 
Email: sales@biopurify.com biopurify@gmail.com
Over 15 years of industry experience in phytochemicals from R&D(reference substances) to Industrialization, please feel free to contact us!

Synonym name: 83377-50-8
Catalogue No.: BP0463
Cas No.: 2680-81-1
Formula: C20H22O4
Mol Weight: 326.392
Botanical Source: Aristolochia pubescens, Krameria grayi, Myristica fragrans (mace) and Piper kadsura

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Can be supplied from milligrams to grams.

For Reference Standard and R&D, Not for Human Use Directly.

Inquire for bulk scale.

 

 

Description:

Dehydrodiisoeugenol has anti-inflammatory activity, it inhibited the expression of the COX-2, proteolysis of inhibitor κB-α and transcriptional activity of NF-κB. Dehydrodiisoeugenol can cross the blood-brain barrier rapidly, it may be developed into an effective anxiogenic agent.

 

References:

Planta Med. 2011 Oct;77(15):1712-7.    

Metabolism of the lignan dehydrodiisoeugenol in rats. 

Dehydrodiisoeugenol (DDIE), a major active lignan from the seed and aril of the fruit of Myristica fragrans Houtt., functions as a potential anti-inflammatory agent by inhibiting lipopolysaccharide-stimulated nuclear factor kappa B activation and cyclooxygenase-2 expression in macrophages. However, the metabolism of DDIE remains unknown. 

METHODS AND RESULTS:

This report describes the metabolic fate of DDIE in liver microsomes, urine, and feces of rats treated with DDIE. DDIE metabolites were isolated by sequential column chromatography and high-performance liquid chromatography from liver microsomes incubations, urine, and feces. Nine metabolites ( M-1 to M-9), including 5 new metabolites, were determined spectroscopically using ultra-violet (UV), mass spectrometry (MS), nuclear magnetic resonance (NMR), and circular dichroism (CD). Analysis of the isolated metabolites showed that DDIE undergoes four major pathways of metabolism in the rat: oxidation (including hydroxylation, hydroformylation, and acetylation), demethylation, ring-opening, and dehydrogenation. In contrast to the metabolites from liver microsomes, the major metabolites In vivo were generated from DDIE by multiple metabolic reactions. 

CONCLUSIONS:

Given these results, we describe a metabolic pathway for DDIE in the rat that gives insight into the metabolism of DDIE and the mechanism of DDIE bioactivity in humans.